Zentalis Pharmaceuticals, Inc. (ZNTL)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Kimberly L. Blackwell |
| Employees: | 160 |
| Web site: | zentalis.com |
|
1359 BROADWAY, SUITE 801, NEW YORK, NY, 10018
(212) 433-3791
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
Please log in first to see chart